I

IUCT Oncopole | Institut Claudius Regaud - Plateforme investigation clinique

Research site
(Unclaimed)
Location
1 avenue irene joliot curie, IUCT-O, Toulouse, Haute-Garonne, France
Site insights

Top conditions

Lymphoma (7 trials)

Leukemia (7 trials)

Myelodysplastic Syndromes (5 trials)

Preleukemia (5 trials)

B-Cell Lymphoma (4 trials)

Top treatments

Azacitidine
Venetoclax
Doxorubicin
Cyclophosphamide
Capsaicin
Decitabine
Darolutamide
EPREX
Durvalumab
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 38
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or w...

Enrolling
Advanced Solid Tumor Cancer
Drug: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
Drug: ABBV-CLS-484

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Niraparib
Drug: Pembrolizumab

The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the r...

Enrolling
ATC
Melanoma
Drug: Trametinib
Drug: CFT1946

This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- d...

Enrolling
Prostate Cancer Metastatic
Drug: Androgen deprivation therapy
Drug: Darolutamide 300 mg

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamid...

Enrolling
Large B-Cell Lymphoma
Drug: Polatuzumab vedotin
Drug: Rituximab

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid)...

Active, not recruiting
Cancer-associated Thrombosis
Drug: Apixaban 5 MG

Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in...

Enrolling
Chronic Myeloid Leukemia
Drug: Venetoclax

This study encompasses two multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trials to assess the antitumor activity...

Enrolling
Metastatic Soft-tissue Sarcoma
Advanced Soft-tissue Sarcoma
Drug: Bintrafusp alfa
Drug: Doxorubicin

Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sar...

Enrolling
Osteosarcoma
Soft Tissue Sarcoma Adult
Drug: Association of pembrolizumab + cabozantinib

This phase I/II open-label, dose-finding, multi-center study will assess safety and primary efficacy of Onureg and Venetoclax combination, to define...

Enrolling
Untreated Myelodysplastic Syndrome
Drug: Onureg + Venetoclax

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with relapsed/refractory acute myel...

Enrolling
Acute
Relapsed
Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)

The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, a...

Active, not recruiting
Classical Hodgkin Lymphoma
Drug: Tislelizumab

Study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemi...

Enrolling
AML
MDS
Drug: venetoclax + azacitidine +/- donor lymphocyte infusion

Trial sponsors

G

Groupe Francophone des Myelodysplasies (7 trials)

Roche logo

Roche (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems